Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Capital Com Bel (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Our Global Offices

Scan to Download ios&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Catalyst Pharmaceuticals - CPRX CFD

13.32
1.76%
0.09
Low: 12.76
High: 13.65
Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 13.09
Open* 12.76
Day's Range* 12.76 - 12.76
1-Year Change* -4.13%
Volume N/A
Average Vol. (3m) 31.7006
52 wk Range N/A
Market Cap 1089.89
P/E Ratio 25.4887
Shares Outstanding 102820000
Revenue 153.717
EPS 0.41587
Dividend (Yield %) N/A
Beta 1.43282
Next Earnings Date Nov 7, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 10, 2022 13.09 1.24 10.46% 11.85 13.20 11.51
Aug 9, 2022 10.59 -0.13 -1.21% 10.72 10.93 10.50
Aug 8, 2022 10.84 -0.35 -3.13% 11.19 11.19 10.63
Aug 5, 2022 11.09 0.58 5.52% 10.51 11.14 10.47
Aug 4, 2022 10.74 0.32 3.07% 10.42 10.87 10.37
Aug 3, 2022 10.46 -0.09 -0.85% 10.55 10.83 10.45
Aug 2, 2022 10.54 0.37 3.64% 10.17 10.74 10.17
Aug 1, 2022 10.24 0.11 1.09% 10.13 10.49 10.01
Jul 29, 2022 10.21 -0.32 -3.04% 10.53 10.67 10.08
Jul 28, 2022 10.57 0.22 2.13% 10.35 10.68 10.14
Jul 27, 2022 10.37 0.35 3.49% 10.02 10.45 9.94
Jul 26, 2022 9.97 0.21 2.15% 9.76 10.21 9.65
Jul 25, 2022 9.88 0.36 3.78% 9.52 9.98 9.51
Jul 22, 2022 9.53 -0.23 -2.36% 9.76 9.81 9.50
Jul 21, 2022 9.84 0.03 0.31% 9.81 9.84 9.68
Jul 20, 2022 9.54 0.23 2.47% 9.31 9.58 9.18
Jul 19, 2022 9.28 0.58 6.67% 8.70 9.46 8.66
Jul 18, 2022 8.64 0.03 0.35% 8.61 9.00 8.60
Jul 15, 2022 8.54 0.11 1.30% 8.43 8.56 8.15
Jul 14, 2022 8.40 0.18 2.19% 8.22 8.55 8.13

Catalyst Pharmaceuticals Events

Time (UTC) Country Event
Monday, November 7, 2022
21:00
  US
Q3 2022 Catalyst Pharmaceuticals Inc Earnings Release
Friday, December 2, 2022
14:00
  US
Catalyst Pharmaceuticals Inc Annual Shareholders Meeting
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 0.5 102.306 119.073 140.833
Revenue 0 0 0.5 102.306 119.073 140.833
Total Operating Expense 19.2802 18.6796 35.7952 70.4831 77.7696 88.448
Selling/General/Admin. Expenses, Total 7.91026 7.3044 15.876 36.8812 44.2337 49.628
Research & Development 11.3699 11.3752 19.9192 18.8428 16.4967 16.936
Operating Income -19.2802 -18.6796 -35.2952 31.8233 41.3032 52.385
Interest Income (Expense), Net Non-Operating 0.88614 -0.1869 0
Other, Net 0.32161 0.45416 1.29165 1.58577 0.5869 0.282
Net Income Before Taxes -18.0725 -18.4124 -34.0035 33.409 41.8901 52.667
Net Income After Taxes -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Net Income Before Extra. Items -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Net Income -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Income Available to Common Excl. Extra. Items -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Income Available to Common Incl. Extra. Items -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Diluted Net Income -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Diluted Weighted Average Shares 82.8753 85.8025 102.634 106.021 106.242 107.796
Diluted EPS Excluding Extraordinary Items -0.21807 -0.21459 -0.33131 0.30065 0.70577 0.36627
Diluted Normalized EPS -0.21807 -0.21459 -0.33131 0.30065 0.70577 0.36627
Total Extraordinary Items 0
Cost of Revenue, Total 14.7591 17.0392 21.884
Gross Profit 87.5472 102.034 118.949
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 30.205 36.365 35.954 38.309 43.089
Revenue 30.205 36.365 35.954 38.309 43.089
Cost of Revenue, Total 4.681 4.545 5.31 7.348 5.89
Gross Profit 25.524 31.82 30.644 30.961 37.199
Total Operating Expense 20.404 20.527 21.95 25.567 25.723
Selling/General/Admin. Expenses, Total 12.716 11.532 12.153 13.227 16.43
Research & Development 3.007 4.45 4.487 4.992 3.403
Operating Income 9.801 15.838 14.004 12.742 17.366
Other, Net 0.081 0.062 0.068 0.071 0.093
Net Income Before Taxes 9.882 15.9 14.072 12.813 17.459
Net Income After Taxes 7.663 12.181 10.329 9.309 13.241
Net Income Before Extra. Items 7.663 12.181 10.329 9.309 13.241
Net Income 7.663 12.181 10.329 9.309 13.241
Income Available to Common Excl. Extra. Items 7.663 12.181 10.329 9.309 13.241
Income Available to Common Incl. Extra. Items 7.663 12.181 10.329 9.309 13.241
Diluted Net Income 7.663 12.181 10.329 9.309 13.241
Diluted Weighted Average Shares 106.68 107.735 107.843 108.754 109.041
Diluted EPS Excluding Extraordinary Items 0.07183 0.11306 0.09578 0.0856 0.12143
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.07183 0.11306 0.09578 0.0856 0.12143
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 41.4538 85.1872 55.1874 111.364 159.244 210.106
Cash and Short Term Investments 40.4058 84.0134 53.4816 94.5188 140.278 191.266
Cash & Equivalents 13.8931 57.4967 16.5594 89.5117 130.237 171.445
Short Term Investments 26.5128 26.5167 36.9222 5.00705 10.0411 19.821
Prepaid Expenses 1.0115 1.11546 1.37761 3.83441 7.79916 4.024
Other Current Assets, Total 0.03644 0.05828 0.27217 0.51667 0.52862 0.327
Total Assets 41.7068 85.3874 60.45 112.376 192.354 237.788
Property/Plant/Equipment, Total - Net 0.2442 0.19139 0.24543 1.00372 0.1298 3.976
Property/Plant/Equipment, Total - Gross 0.35768 0.35055 0.44257 4.251
Accumulated Depreciation, Total -0.11348 -0.15917 -0.19715 -0.275
Other Long Term Assets, Total 0.00889 0.00889 0.00889 0.00889 32.9801 23.706
Total Current Liabilities 2.09454 4.26616 9.51135 24.0987 22.7563 27.063
Accounts Payable 0.93318 1.94558 2.33737 4.11745 4.25602 2.768
Accrued Expenses 1.14327 2.27254 7.07414 16.7403 18.0832 23.973
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.01809 0.04805 0.09984 3.24103 0.41703 0.322
Total Liabilities 2.39792 4.42362 9.66615 24.7463 22.7563 30.957
Total Long Term Debt 0 0 0 0 0 0
Other Liabilities, Total 0.30339 0.15746 0.1548 0.64753 0 3.894
Total Equity 39.3089 80.9638 50.7838 87.63 169.598 206.831
Common Stock 0.08297 0.10255 0.10274 0.1034 0.10378 0.103
Additional Paid-In Capital 147.374 207.422 211.265 216.206 223.168 233.186
Retained Earnings (Accumulated Deficit) -108.148 -126.56 -160.564 -128.689 -53.7056 -26.31
Total Liabilities & Shareholders’ Equity 41.7068 85.3874 60.45 112.376 192.354 237.788
Total Common Shares Outstanding 82.9723 102.549 102.739 103.397 103.782 102.993
Redeemable Preferred Stock 0 0 0 0 0
Total Inventory 0.05601 1.95679 4.6506 7.87
Long Term Investments 5.00824 0
Other Equity, Total -0.02025 0.00951 0.03133 -0.148
Total Receivables, Net 10.537 5.98743 6.619
Accounts Receivable - Trade, Net 10.537 5.98743 6.619
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 161.533 176.305 192.795 210.106 221.191
Cash and Short Term Investments 143.299 155.275 174.792 191.266 197.796
Cash & Equivalents 127.328 135.295 154.836 171.445 178.372
Short Term Investments 15.971 19.98 19.956 19.821 19.424
Total Receivables, Net 5.601 6.292 6.625 6.619 10.552
Accounts Receivable - Trade, Net 5.601 6.292 6.625 6.619 10.552
Total Inventory 4.39 7.097 6.95 7.87 7.827
Prepaid Expenses 7.967 7.32 4.2 4.024 4.583
Other Current Assets, Total 0.276 0.321 0.228 0.327 0.433
Total Assets 197.216 209.13 223.248 237.788 246.972
Property/Plant/Equipment, Total - Net 4.253 4.115 4.044 3.976 3.882
Property/Plant/Equipment, Total - Gross 4.433 4.326 4.286 4.251 4.191
Accumulated Depreciation, Total -0.18 -0.211 -0.242 -0.275 -0.309
Other Long Term Assets, Total 31.43 28.71 26.409 23.706 21.899
Total Current Liabilities 14.436 16.135 20.614 27.063 22.938
Accounts Payable 2.561 2.924 2.752 2.768 5.139
Accrued Expenses 10.664 13.099 17.752 23.973 15.278
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.211 0.112 0.11 0.322 2.521
Total Liabilities 18.565 20.186 24.587 30.957 26.751
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.129 4.051 3.973 3.894 3.813
Total Equity 178.651 188.944 198.661 206.831 220.221
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.104 0.103 0.103 0.103 0.103
Additional Paid-In Capital 224.927 226.699 231.165 233.186 236.191
Retained Earnings (Accumulated Deficit) -46.335 -37.821 -32.544 -26.31 -15.62
Other Equity, Total -0.045 -0.037 -0.063 -0.148 -0.453
Total Liabilities & Shareholders’ Equity 197.216 209.13 223.248 237.788 246.972
Total Common Shares Outstanding 103.805 103.162 103.153 102.993 102.957
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -18.0725 -18.4124 -34.0035 31.8753 74.983 39.482
Cash From Operating Activities -17.9635 -13.7426 -25.7044 34.6115 45.0349 60.372
Cash From Operating Activities 0.04341 0.04569 0.03798 0.05433 0.09207 0.192
Non-Cash Items 0.94995 2.59487 3.55064 3.77741 7.04198 6.36
Changes in Working Capital -0.88441 2.02925 4.71049 -1.0956 -4.11092 5.022
Cash From Investing Activities 3.55257 -0.00396 -15.526 37.2246 -5.0114 -11.021
Capital Expenditures -0.09606 0 -0.09202 -0.01937 -0.0114 -1.021
Other Investing Cash Flow Items, Total 3.64863 -0.00396 -15.434 37.244 -5 -10
Cash From Financing Activities 0.06899 57.3502 0.29312 1.11624 0.70193 -8.143
Financing Cash Flow Items -0.01127 0 -0.00445 0 -0.0562 -0.153
Issuance (Retirement) of Stock, Net 0.08025 57.3502 0.29756 1.11624 0.75813 -7.99
Net Change in Cash -14.342 43.6036 -40.9373 72.9523 40.7254 41.208
Deferred Taxes -32.9713 9.316
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 7.663 19.844 30.173 39.482 13.241
Cash From Operating Activities 3.814 19.489 41.196 60.372 8.478
Cash From Operating Activities 0.097 0.128 0.159 0.192 0.034
Deferred Taxes 1.55 4.27 6.571 9.316 1.901
Non-Cash Items 1.565 3.191 4.808 6.36 1.961
Changes in Working Capital -7.061 -7.944 -0.515 5.022 -8.659
Cash From Investing Activities -6.911 -10.912 -10.98 -11.021 0
Capital Expenditures -0.911 -0.912 -0.98 -1.021 0
Other Investing Cash Flow Items, Total -6 -10 -10 -10 0
Cash From Financing Activities 0.188 -3.519 -5.617 -8.143 -1.551
Issuance (Retirement) of Stock, Net 0.188 -3.502 -5.6 -7.99 -1.551
Net Change in Cash -2.909 5.058 24.599 41.208 6.927
Financing Cash Flow Items -0.017 -0.017 -0.153
Cash Taxes Paid 0.041

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Catalyst Pharmaceuticals Company profile

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Catalyst Pharmaceuticals Inc revenues increased 18% to $140.8M. Net income decreased 47% to $39.5M. Revenues reflect Revenues increase of 16% to $138M. Net income was offset by Selling, general and adminis - Balancing increase of 14% to $45.2M (expense), reasear increase of 3% to $15.3M (expense), Other income, net decrease of 52% to $282K (income).

Equity composition

Common Stock $.001 Par, 4/11, 100M auth., 21,654,680 issd. Insiders own 22.54%. IPO 8/11/06, 3,350,000 shares @ $6 per share by First Albany Capital Inc. and Stifel, Nicolaus & Company, Incorporated. 9/08, P.O of 1.5M shares.

Industry: Pharmaceuticals (NEC)

355 Alhambra Circle
Suite 801
CORAL GABLES
FLORIDA 33134
US

Income statement

News

Photo of cell phone in hand

Crypto market wrap: Unknown coin and household name shine

ANKR spikes on Binance deal and ether flirts with $1,900 thanks to Merge Mania

23:12, 11 August 2022
A file photo of a Rivian R1T electric truck is seen outside Munro & Associates headquarters in Auburn Hills, Michigan, U.S., June 3, 2022.

EV maker Rivian expects wider operating loss for year

Rivian beat quarterly revenue estimates as a ramp-up in production helped it deliver more SUVs, pickup trucks and vans.

20:11, 11 August 2022
A file photo of a worker walking past oil pipes at a refinery in Wuhan, Hubei province March 23, 2012.

Oil output halted at 7 U.S. Gulf platforms on pipeline outage

The shut-ins could halt about 600,000 barrels per day of oil production

18:28, 11 August 2022
Illustration of trading oil - changing crude prices on the market

Trading oil: Here’s what could impact the price of crude

A look at factors that could change oil prices in the coming weeks

17:58, 11 August 2022
A file photo shows the U.S. Securities and Exchange Commission logo on an office door at the SEC headquarters in Washington, June 24, 2011.

SEC investigating hedge fund and WallStreetBets nemesis Melvin Capital Management: WSJ

The SEC is looking into Melvin Capital Management’s risk controls and investor disclosures after the hedge fund was hammered by the meme-stock rally last year, the Wall Street Journal reported on Thursday.

15:50, 11 August 2022

People Also Watch

US Crude Oil Spot

93.28 Price
+2.510% 1D Chg, %
Long position overnight fee 0.0224%
Short position overnight fee -0.1354%
Overnight fee time 21:00 (UTC)
Spread 0.03

Market analysis

AMC icon on a mobile screen

AMC short squeeze: Interest and positions on the rise again amid meme stock resurgence

16:26, 11 August 2022
USA and Sri Lanka currencies codes on national flags background. International money transfer concept

USD/LKR forecast: Will the Sri Lankan rupee keep falling?

15:15, 11 August 2022
iExec RLC, RLC coin crypto currency logo banner, wallpaper on isolated background.

iExec RLC price prediction: What is iExec RLC?

14:33, 11 August 2022

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading